-
Morphological Profiling Reveals HSPB7 Rescue in Titin DCM
2026-09-27
The CARDIO high-content imaging assay identified distinct morphological and functional effects of YWHAE and HSPB7 knockout in human stem cell-derived cardiomyocytes. Follow-up engineered heart tissue experiments found that HSPB7 loss could restore contractile function in a titin-deficiency model, highlighting morphological profiling as a way to find genetic modifiers for further testing.
-
ATRNL1 and Cell-Specific Signals in Atrial Fibrillation
2026-09-26
A large-scale single-nucleus RNA-seq study of human left atrial tissue identifies cardiomyocytes and macrophages as the cell populations with substantial AF-associated transcriptional changes, and highlights ATRNL1 in cardiomyocyte stress responses and electrical activity. The findings offer a cell-specific framework for investigating AF biology, while requiring further validation before ATRNL1 can be considered a clinical target.
-
Z-VEID-FMK: Practical Caspase-6 Assay Guidance
2026-09-25
A scenario-based guide to using Z-VEID-FMK (SKU A1923) to investigate caspase-6 involvement in apoptosis assays. It covers experimental controls, the product-reported starting condition and solubility, interpretation limits, and practical vendor-selection criteria.
-
Isotope-Diluted UHPLC–MS/MS for Methylated Purines
2026-09-25
Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS method that improves signal response and separates closely related methylated purine nucleosides, including m1A and m6A. Its combination of chromatographic resolution and sample cleanup enabled sensitive intracellular measurements, offering a useful analytical foundation for RNA modification research and future biomarker studies.
-
Entinostat (MS-275): Better Cancer Drug Response Assays
2026-09-24
Use Entinostat to probe class I HDAC inhibition while separating slowed growth from actual cancer-cell killing. This workflow pairs dose and time-course testing with orthogonal viability and death readouts for more interpretable results.
-
Doxorubicin Hydrochloride: Beyond Cell Death
2026-09-24
Doxorubicin hydrochloride is often evaluated through a single viability endpoint, but cardiac injury involves distinct, overlapping stress and death signals. This article connects a mouse cardiotoxicity study to a more discriminating approach for interpreting doxorubicin assays.
-
Necrostatin 2: Separating Necroptosis from Ferroptosis
2026-09-23
Necrostatin 2 (Nec-2) can help investigate necroptosis, but membrane rupture alone does not identify the death pathway. This article connects Nec-2 experiments with new evidence on ferroptosis and TMEM16F to help researchers design more discriminating assays.
-
NOXA–BCL-XL/MCL-1 Balance in Rhabdomyosarcoma
2026-09-23
A 2021 Neoplasia study used patient-derived xenograft (PDX) primary rhabdomyosarcoma cells to identify ABT-263 (Navitoclax) as a potent re-sensitizer to first-line chemotherapy. Its mechanistic analysis implicates the balance between pro-apoptotic NOXA and the anti-apoptotic proteins BCL-XL and MCL-1 as a determinant of treatment response, offering a model for studying relapse-associated drug resistance.
-
MDM1, p53, and Chemoradiotherapy Response in CRC
2026-09-22
The 2025 Cancer Biology & Medicine study identifies MDM1 as both a potential biomarker and mechanistic regulator of chemoradiotherapy sensitivity in colorectal cancer. Its experiments connect MDM1 overexpression with reduced YBX1 binding at the TP53 promoter, increased p53 expression, and enhanced apoptosis, suggesting a framework for patient stratification and resistance research.
-
When Blocking Apoptosis Clarifies Cancer Biology
2026-09-22
Z-VAD-FMK can do more than suppress apoptotic readouts: it can help translational researchers test whether caspase-dependent death is causal, consequential, or incidental in cancer models. This article connects mechanistic biology, assay strategy, and product selection to findings from ovarian cancer-associated muscle wasting research.
-
Berberrubine and Urate Transporter Regulation in HUA
2026-09-21
The reference study shows that berberrubine reduces chemically induced hyperuricemia in mice through coordinated effects on urate production, renal transporter expression, inflammation, and JAK2/STAT3 signaling. Its value lies in connecting serum urate lowering with renal protection and mechanistic biomarker analysis, while its short-term animal design limits direct clinical translation.
-
Erastin Ferroptosis Workflows for Cancer Research
2026-09-21
Erastin provides an upstream redox-stress challenge for testing cystine metabolism, lipid peroxidation, and genotype-linked tumor vulnerability. This practical guide combines a 10 μM, 24-hour starting workflow with orthogonal validation and translates melanocyte ferroptosis findings into better assay design.
-
Neuroligin 1, PKC, and Repetitive Behavior
2026-09-20
This Advanced Science study identifies a cell-type-specific mechanism linking Neuroligin 1 loss in dorsal-striatal D2 medium spiny neurons to autistic-like self-grooming and digging. Its combination of behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation implicates excessive PKC signaling as a modifiable contributor rather than a standalone explanation for repetitive behavior.
-
Necrostatin 2 (Nec-2): Assay Guide
2026-09-19
A scenario-based guide to using Necrostatin 2 (Nec-2), SKU A3652, to separate necroptosis-related viability loss from nonspecific cytotoxicity. It covers assay controls, compound handling, protocol optimization, interpretation, and practical product-selection criteria.
-
PR-619: Practical DUB Inhibition Workflow
2026-09-18
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for examining ubiquitinated-protein accumulation without directly blocking proteasomal catalytic activity. It is suitable for controlled cell-based ubiquitination and autophagy experiments, but its broad target profile, low-micromolar cytotoxicity, and limited product-dossier evidence require concentration-response testing and parallel viability controls.